Cipla Palliative Care Centre completes 15 years of caring for advanced stage cancer patients

Tools

Cipla Palliative Care Centre completes 15 years of caring for advanced stage cancer patients
~Announces another major price reduction on select cancer drugs~


India, Mumbai, 8th November, 2012: Cipla has always been committed to the treatment and care of cancer patients. As part of this commitment, in 1997, it established the Cipla Palliative Care and Training Centre in Pune, to provide care to advanced stage cancer patients. Today, it is one of the few centres in India offering the best-in class palliative care to cancer patients. The Centre provides free treatment and has cared for over 8,000 patients till date. It has also trained a large number of nurses in advanced palliative care. For more information on the Cipla Palliative Care and Training Centre, please visit www.carebeyondcure.org


In continuation with its commitment to make medicines affordable and accessible, particularly in anti-cancer medication, in May 2012, Cipla announced a dramatic price cut in three major anti-cancer drugs - Sorafenib (SORANIB), Gefitinib (GEFTICIP) and Temozolomide (TEMOSIDE).


Following the overwhelming response on the price cut received from the patients & their families and doctors, Cipla is now announcing another breakthrough price reduction in three additional anti-cancer drugs - Erlotinib (ERLOCIP), Docetaxel (DOCETAX) and Capecitabine (CAPEGARD). These drugs are for the treatment of Lung and Pancreatic Cancer, Breast Cancer, Head & Neck Cancer, Gastric Cancer, Bladder, Colorectal and Colon Cancers. The revised prices for the selected products are stated below:


Indication
Molecule
Brand Name
Current Price (Rs.)
Revised Price (Rs.)
Reduction (Rs.)
Lung Cancer (Metastatic non-small cell cancer)
Erlotinib
ERLOCIP 150
30 tablets
27,000
9,900
17,100
ERLOCIP 150
10 tablets
10,000
3,700
6,300
ERLOCIP 100
30 tablets
18,000
6,600
11,400
Breast Cancer, Lung Cancer (Non-small cell & Small Cell), Head & Neck Cancer, Gastric Cancer, Bladder Cancer
Docetaxel
DOCETAX 20 mg
3,300
1,650
1,650
DOCETAX 80 mg
10,000
5,000
5,000
DOCETAX 120 mg
14,000
7,000
7,000
Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Colon Cancer
Capecitabine
CAPEGARD 500 mg
10 tablets
1,200
600
600


"Continuing its contribution towards affordable and accessible treatment for patients, Cipla extends the work done in HIV/AIDS and Malaria to now include Cancer, not only in India but globally," announced Dr. Y.K. Hamied, Chairman and Managing Director, Cipla Limited.

About Cipla
Cipla laid the foundation for the Indian pharmaceutical industry in 1935, with the vision to make India self-reliant in healthcare. Over the years, Cipla has emerged as one of the most respected names not just in India but worldwide. Its state-of-the-art R&D centre has given the country and the world many firsts. This includes the revolutionary AIDS cocktail for less than a dollar a day. The company has over 34 manufacturing facilities across India, and manufactures 2,000+ products in 65 therapeutic categories.
With a turnover of over US $ 1.4 billion, Cipla serves doctors and patients in over 170 countries. It has earned a name for maintaining one global standard across all its products and services. Cipla continues to support, improve and save millions of lives with its high-quality drugs and innovative devices.

Visit www.cipla.com

Media Contact:
Antara Mukherjee Jaisingh Balakrishnan
Head – Corporate Communications Corporate Communications
Mob: (+91) 9967516441 Mob: (+91) 9833836185
E Mail: antara.mukherjee@cipla.com E Mail: jaisingh.krishnan@cipla.com